151 related articles for article (PubMed ID: 38462432)
1. Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
Moro PL; Carlock G; Fifadara N; Habenicht T; Zhang B; Strid P; Marquez P
Vaccine; 2024 Apr; 42(9):2380-2384. PubMed ID: 38462432
[TBL] [Abstract][Full Text] [Related]
2. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System.
Moro PL; Olson CK; Zhang B; Marquez P; Strid P
Obstet Gynecol; 2022 Sep; 140(3):421-427. PubMed ID: 35926203
[TBL] [Abstract][Full Text] [Related]
3. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
Moro PL; Olson CK; Clark E; Marquez P; Strid P; Ellington S; Zhang B; Mba-Jonas A; Alimchandani M; Cragan J; Moore C
Vaccine; 2022 May; 40(24):3389-3394. PubMed ID: 35489985
[TBL] [Abstract][Full Text] [Related]
4. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
5. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
6. Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
Moro PL; Ennulat C; Brown H; Woody G; Zhang B; Marquez P; Woo EJ; Su JR
Drug Saf; 2024 May; 47(5):487-493. PubMed ID: 38411838
[TBL] [Abstract][Full Text] [Related]
7. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
[TBL] [Abstract][Full Text] [Related]
8. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
9. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016.
Moro PL; Zheteyeva Y; Barash F; Lewis P; Cano M
Vaccine; 2018 Jan; 36(1):50-54. PubMed ID: 29174107
[TBL] [Abstract][Full Text] [Related]
10. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
[TBL] [Abstract][Full Text] [Related]
11. Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis.
Santi Laurini G; Montanaro N; Motola D
Eur J Clin Pharmacol; 2023 May; 79(5):657-661. PubMed ID: 36961579
[TBL] [Abstract][Full Text] [Related]
12. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt JG; Thompson D; Su JR; Myers TR; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(28):899-903. PubMed ID: 35834416
[TBL] [Abstract][Full Text] [Related]
13. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
[TBL] [Abstract][Full Text] [Related]
14. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
Moro P; Baumblatt J; Lewis P; Cragan J; Tepper N; Cano M
Drug Saf; 2017 Feb; 40(2):145-152. PubMed ID: 27988883
[TBL] [Abstract][Full Text] [Related]
16. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
[TBL] [Abstract][Full Text] [Related]
17. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
Shimabukuro TT; Kim SY; Myers TR; Moro PL; Oduyebo T; Panagiotakopoulos L; Marquez PL; Olson CK; Liu R; Chang KT; Ellington SR; Burkel VK; Smoots AN; Green CJ; Licata C; Zhang BC; Alimchandani M; Mba-Jonas A; Martin SW; Gee JM; Meaney-Delman DM;
N Engl J Med; 2021 Jun; 384(24):2273-2282. PubMed ID: 33882218
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
19. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
Jacobs JW; Booth GS; Adkins BD
Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
[TBL] [Abstract][Full Text] [Related]
20. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
